share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股SEC公告 ·  09/20 08:02

Moomoo AI 已提取核心信息

Alterity Therapeutics Limited, a development stage enterprise, has filed a Form 6-K with the SEC for the month of September 2024, indicating a change in director's interest notices. The report, which is incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3, details changes in the holdings of directors Mr. Brian Meltzer and Mr. Peter Marks. On August 31, 2024, Mr. Meltzer disposed of 7,142,857 unlisted options, resulting in a direct holding of 7,142,857 shares and 9,380,952 options. Similarly, Mr. Marks saw an indirect disposal of 7,142,857 unlisted options, leaving him with an indirect interest in 7,185,986 shares and 2,380,952 options. The changes in holdings are due to the expiry of options without exercise or conversion. The report confirms that these transactions did not occur during a closed period requiring prior written clearance.
Alterity Therapeutics Limited, a development stage enterprise, has filed a Form 6-K with the SEC for the month of September 2024, indicating a change in director's interest notices. The report, which is incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3, details changes in the holdings of directors Mr. Brian Meltzer and Mr. Peter Marks. On August 31, 2024, Mr. Meltzer disposed of 7,142,857 unlisted options, resulting in a direct holding of 7,142,857 shares and 9,380,952 options. Similarly, Mr. Marks saw an indirect disposal of 7,142,857 unlisted options, leaving him with an indirect interest in 7,185,986 shares and 2,380,952 options. The changes in holdings are due to the expiry of options without exercise or conversion. The report confirms that these transactions did not occur during a closed period requiring prior written clearance.
alterity therapeutics有限公司，一家处于发展阶段的企业，已向美国证券交易委员会（SEC）提交了2024年9月的6-k表单，表明董事利益通知发生了变化。该报告已纳入公司在S-8表和F-3表上的注册声明中，详细说明了董事Brian Meltzer先生和Peter Marks先生持股的变化情况。2024年8月31日，Meltzer先生处置了7,142,857股未上市期权，直接持有7,142,857股股份和9,380,952个期权。同样，Marks先生间接处置了7,142,857股未上市期权，使他间接持有7,185,986股股份和2,380,952个期权。持股的变化是由于期权到期而未行使或转换。报告确认这些交易没有发生在需要提前书面批准的封闭期间。
alterity therapeutics有限公司，一家处于发展阶段的企业，已向美国证券交易委员会（SEC）提交了2024年9月的6-k表单，表明董事利益通知发生了变化。该报告已纳入公司在S-8表和F-3表上的注册声明中，详细说明了董事Brian Meltzer先生和Peter Marks先生持股的变化情况。2024年8月31日，Meltzer先生处置了7,142,857股未上市期权，直接持有7,142,857股股份和9,380,952个期权。同样，Marks先生间接处置了7,142,857股未上市期权，使他间接持有7,185,986股股份和2,380,952个期权。持股的变化是由于期权到期而未行使或转换。报告确认这些交易没有发生在需要提前书面批准的封闭期间。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间